Vitreous Inflammation Associated with Intravitreal Anti-VEGF Pharmacotherapy
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Vascular endothelial growth factor (VEGF) is a potent promoter of angiogenesis involved in a wide variety of physiologic processes. Intravitreal injections targeting VEGF have transformed the treatment of neovascular retinal diseases. Currently, there are four anti-VEGF agents in use: bevacizumab, ranibizumab, pegaptanib, and aflibercept. The success and frequency of anti-VEGF therapy have made the ocular safety profile of these agents of vital importance. This paper focuses on sterile endophthalmitis. In this paper, we compare the incidences of posttreatment sterile endophthalmitis among the four agents, review the mechanism of actions, and discuss the most prevalent hypotheses leading to sterile endophthalmitis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fundamentally, we must acknowledge eye contains immune-privileged sites with the potential for unique immune-related responses [83].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [83]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687 · cited 3×
“VEGF165 has properties of both the diffusible and bound form of VEGF [1].”
BackgroundInfluentialRanibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Investigative Ophthalmology and Visual Science
Frey, C. (2010) · Cited by 3,350
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
Ng, E. W. M., Shima, D. T., Calias, P., Cunningham, E. T., Guyer, D. R., & Adamis, A. P. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1955 · Cited by 1,588
Papadopoulos, N., Martin, J., Ruan, Q., Rafique, A., Rosconi, M. P., Shi, E., Pyles, E. A., Yancopoulos, G. D., Stahl, N., & Wiegand, S. J. (2012) · Angiogenesis · doi:10.1007/s10456-011-9249-6 · Cited by 1,037
Rosenfeld, P. J., Moshfeghi, A. A., & Puliafito, C. A. (2005) · Ophthalmic Surgery, Lasers and Imaging Retina · doi:10.3928/1542-8877-20050701-14 · Cited by 904 · cited 1×
“Hindawi Publishing Corporation Mediators of Inflammation Volume 2013, Article ID 943409, 6 pages http://dx.doi.org/10.1155/2013/943409”
BackgroundInfluentialRegillo, C. D., Brown, D. M., Abraham, P., Yue, H., Ianchulev, T., Schneider, S., & Shams, N. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.10.004 · Cited by 858
FERRARA, N., DAMICO, L., SHAMS, N., LOWMAN, H., & KIM, R. (2006) · Retina · doi:10.1097/01.iae.0000242842.14624.e7 · Cited by 849
Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration
Chakravarthy, U., Harding, S. P., Rogers, C. A., Downes, S. M., Lotery, A. J., Wordsworth, S., & Reeves, B. C. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.04.015 · Cited by 781
Pharmacokinetics of Intravitreal Bevacizumab (Avastin)
Bakri, S. J., Snyder, M. R., Reid, J. M., Pulido, J. S., & Singh, R. J. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.01.017 · Cited by 683
Ho, A. C., Busbee, B. G., Regillo, C. D., Wieland, M. R., Van Everen, S. A., Li, Z., Rubio, R. G., & Lai, P. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.05.009 · Cited by 590
Busbee, B. G., Ho, A. C., Brown, D. M., Heier, J. S., Suñer, I. J., Li, Z., Rubio, R. G., & Lai, P. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.10.014 · Cited by 500
Rosenfeld, P. J., Fung, A. E., & Puliafito, C. A. (2005) · Ophthalmic Surgery, Lasers and Imaging Retina · doi:10.3928/1542-8877-20050701-15 · Cited by 489 · cited 1×
“Hindawi Publishing Corporation Mediators of Inflammation Volume 2013, Article ID 943409, 6 pages http://dx.doi.org/10.1155/2013/943409”
BackgroundInfluentialWu, L., Martínez-Castellanos, M. A., Quiroz-Mercado, H., Arevalo, J. F., Berrocal, M. H., Farah, M. E., Maia, M., Roca, J. A., Rodriguez, F. J., & for the Pan American Collaborative Retina Group (PACORES) (2007) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-007-0660-z · Cited by 456
Holz, F. G., Amoaku, W., Donate, J., Guymer, R. H., Kellner, U., Schlingemann, R. O., Weichselberger, A., & Staurenghi, G. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2010.12.019 · Cited by 413
Intraocular Pharmacokinetics of Bevacizumab After a Single Intravitreal Injection in Humans
Krohne, T. U., Eter, N., Holz, F. G., & Meyer, C. H. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2008.05.036 · Cited by 363 · cited 1×
“While infective endophthalmitis cases are heavily treated by intravitreal antibiotics, the treatment of sterile endophthalmitis has shown prompt improvement with topical steroid therapy [8].”
BackgroundHeier, J. S. (2006) · Archives of Ophthalmology · doi:10.1001/archopht.124.11.1532 · Cited by 304
Systemic and Ocular Safety of Intravitreal Anti-VEGF Therapies for Ocular Neovascular Disease
Tolentino, M. (2011) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2010.08.006 · Cited by 304 · cited 2×
“Signs Blurred vision [11], anterior segment inflammation greater than posterior inflammation [10, 17, 18, 21, 22] Decreased vision, severe anterior segment reaction (fibrin and hypopyon), and vitritis [14]”
BackgroundChun, D. W., Heier, J. S., Topping, T. M., Duker, J. S., & Bankert, J. M. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.04.033 · Cited by 295
A review of clinical trials of anti-VEGF agents for diabetic retinopathy
Nicholson, B. P., & Schachat, A. P. (2010) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-010-1315-z · Cited by 272 · cited 1×
“Hindawi Publishing Corporation Mediators of Inflammation Volume 2013, Article ID 943409, 6 pages http://dx.doi.org/10.1155/2013/943409”
BackgroundInfluentialKoren, E., Zuckerman, L., & Mire-Sluis, A. (2002) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201023378175 · Cited by 267
Pegaptanib Sodium for Neovascular Age-Related Macular Degeneration
D’Amico, D. J. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.02.027 · Cited by 260
Acute in vivo effects of human recombinant tumor necrosis factor.
Remick, D. G., Kunkel, R. G., Larrick, J. W., & Kunkel, S. L. (1987) · PubMed · Cited by 256
Intraocular Pharmacokinetics of Ranibizumab Following a Single Intravitreal Injection in Humans
Krohne, T. U., Liu, Z., Holz, F. G., & Meyer, C. H. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2012.03.047 · Cited by 238
Shah, C. P., Garg, S. J., Vander, J. F., Brown, G. C., Kaiser, R. S., & Haller, J. A. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.02.034 · Cited by 231 · cited 2×
“Also, in order to avoid confusion, only the studies reporting noninfectious endophthalmitis were included.”
BackgroundDrolet, D. W., Nelson, J., Tucker, C. E., Zack, P. M., Nixon, K., Bolin, R., Judkins, M. B., Farmer, J. A., Wolf, J. L., Gill, S. C., et al. (2000) · Pharmaceutical Research · doi:10.1023/a:1007657109012 · Cited by 206 · cited 1×
“In the literature, the incidence of sterile endophthalmitis after intravitreal anti-VEGF therapy ranges between 0.033% and 2.9% [9–14].”
BackgroundInfluentialComplications in patients after intravitreal injection of bevacizumab
Shima, C., Sakaguchi, H., Gomi, F., Kamei, M., Ikuno, Y., Oshima, Y., Sawa, M., Tsujikawa, M., Kusaka, S., & Tano, Y. (2008) · Acta Ophthalmologica · doi:10.1111/j.1600-0420.2007.01067.x · Cited by 200 · cited 1×
“Sterile endophthalmitis (also known as “pseudoendophthalmitis”) is described as any acute intraocular inflammation without infection that resolves without antibiotic treatment, unlike true endophthalmitis.”
BackgroundAntoszyk, A. N., Tuomi, L., Chung, C. Y., & Singh, A. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.12.029 · Cited by 190
Rosenfeld, P. J., Heier, J. S., Hantsbarger, G., & Shams, N. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.01.027 · Cited by 189
Zhu, Q., Ziemssen, F., Henke‐Fahle, S., Tatar, O., Szurman, P., Aisenbrey, S., Schneiderhan‐Marra, N., Xu, X., & Grisanti, S. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2008.04.023 · Cited by 157 · cited 1×
“While infective endophthalmitis cases are heavily treated by intravitreal antibiotics, the treatment of sterile endophthalmitis has shown prompt improvement with topical steroid therapy [8].”
BackgroundSingerman, L. J., Masonson, H., Patel, M., Adamis, A. P., Buggage, R., Cunningham, E., Goldbaum, M., Katz, B., & Guyer, D. (2008) · British Journal of Ophthalmology · doi:10.1136/bjo.2007.132597 · Cited by 132
Wickremasinghe, S. S., Michalova, K., Gilhotra, J., Guymer, R. H., Harper, C. A., Wong, T. Y., & Qureshi, S. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2008.05.007 · Cited by 124 · cited 1×
“Sterile endophthalmitis (also known as “pseudoendophthalmitis”) is described as any acute intraocular inflammation without infection that resolves without antibiotic treatment, unlike true endophthalmitis.”
BackgroundGeorgopoulos, M., Polak, K., Prager, F., Prunte, C., & Schmidt-Erfurth, U. (2009) · British Journal of Ophthalmology · doi:10.1136/bjo.2008.138479 · Cited by 124
LADAS, I. D., KARAGIANNIS, D. A., ROUVAS, A. A., KOTSOLIS, A. I., LIOTSOU, A., & VERGADOS, I. (2009) · Retina · doi:10.1097/iae.0b013e31819a5f98 · Cited by 122
Ho, V. Y., Yeh, S., Olsen, T. W., Bergstrom, C. S., Yan, J., Cribbs, B. E., & Hubbard, G. B. (2013) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.02.009 · Cited by 122
Intraocular inflammation following intravitreal injection of bevacizumab
Bakri, S. J., Larson, T. A., & Edwards, A. O. (2008) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-007-0754-7 · Cited by 102 · cited 1×
“Sterile endophthalmitis (also known as “pseudoendophthalmitis”) is described as any acute intraocular inflammation without infection that resolves without antibiotic treatment, unlike true endophthalmitis.”
BackgroundSevere Intraocular Inflammation after Intravitreal Injection of Bevacizumab
Sato, T., Emi, K., Ikeda, T., Bando, H., Sato, S., Morita, S., Oyagi, T., & Sawada, K. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2009.07.041 · Cited by 84 · cited 1×
“Sterile endophthalmitis (also known as “pseudoendophthalmitis”) is described as any acute intraocular inflammation without infection that resolves without antibiotic treatment, unlike true endophthalmitis.”
BackgroundRate of serious adverse effects in a series of bevacizumab and ranibizumab injections
Sharma, S., Johnson, D. E., Abouammoh, M. A., Hollands, S., & Brissette, A. R. (2012) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2012.03.026 · Cited by 80
Wang, F., Yu, S., Liu, K., Chen, F.-E., Song, Z., Zhang, X., Xu, X., & Sun, X. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.07.083 · Cited by 80
Aflibercept-Related Sterile Inflammation
Hahn, P., Kim, J. E., Stinnett, S., Chung, M. M., Dugel, P. U., Flynn, H. W., Huang, S. S., Sadda, S. R., & Mahmoud, T. H. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.11.018 · Cited by 74
Interferon immunogenicity: technical evaluation of interferon-alpha 2a.
Hochuli, E. (1997) · PubMed · Cited by 71
Chong, D. Y., Anand, R., Williams, P. D., Qureshi, J. A., & Callanan, D. G. (2010) · Retina · doi:10.1097/iae.0b013e3181dc04da · Cited by 66 · cited 2×
“Also, in order to avoid confusion, only the studies reporting noninfectious endophthalmitis were included.”
BackgroundSTERILE ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB OBTAINED FROM A SINGLE BATCH
YAMASHIRO, K., TSUJIKAWA, A., MIYAMOTO, K., OH, H., OTANI, A., TAMUARA, H., OOTO, S., SASAHARA, M., IWAMA, D., & YOSHIMURA, N. (2010) · Retina · doi:10.1097/iae.0b013e3181bd2d51 · Cited by 64
Pharmacokinetic Properties of Intravitreal I-124-Aflibercept in a Rabbit Model Using PET/CT
Christoforidis, J. B., Williams, M. M., Kothandaraman, S., Kumar, K., Epitropoulos, F. M., & Knopp, M. V. (2012) · Current Eye Research · doi:10.3109/02713683.2012.727521 · Cited by 63 · cited 1×
“Meta-analyses reports have shown variability in the incidence of sterile endophthalmitis between the different anti-VEGF agents (Table 2).”
BackgroundSelf-citationChristoforidis, J. B., Carlton, M. M., Knopp, M. V., & Hinkle, G. H. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6862 · Cited by 63 · cited 1×
“Meta-analyses reports have shown variability in the incidence of sterile endophthalmitis between the different anti-VEGF agents (Table 2).”
BackgroundSelf-citationNazari, H. K., Modarres, M., Parvaresh, M. M., & Falavarjani, K. G. (2010) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-010-1430-x · Cited by 60 · cited 1×
“Hindawi Publishing Corporation Mediators of Inflammation Volume 2013, Article ID 943409, 6 pages http://dx.doi.org/10.1155/2013/943409”
BackgroundInfluentialFalavarjani, K. G., Modarres, M., & Nazari, H. K. (2009) · Eye · doi:10.1038/eye.2009.94 · Cited by 59
de Lima, L. H. S. G., Zweifel, S. A., Engelbert, M., Sorenson, J. A., Slakter, J. S., Cooney, M. J., Klancnik, J. M., Yannuzzi, L. A., & Freund, K. B. (2009) · Retina · doi:10.1097/iae.0b013e3181b32d27 · Cited by 56
Uveitis Following Intravitreal Bevacizumab: A Non-Infectious Cluster
Kay, C. N., Tarantola, R. M., Gehrs, K. M., Folk, J. C., Mahajan, V. B., Boldt, H. C., Syed, N. A., & Russell, S. R. (2011) · Ophthalmic Surgery, Lasers and Imaging Retina · doi:10.3928/15428877-20110603-04 · Cited by 37
Johnson, D. E., Hollands, H., Hollands, S., & Sharma, S. (2010) · Canadian Journal of Ophthalmology · doi:10.3129/i10-013 · Cited by 37 · cited 2×
“(2010) [26] Bevacizumab 173 693 1.”
Johnson, D. E., & Sharma, S. (2013) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e32835f8ec0 · Cited by 36
Acute Anterior Uveitis Following Intravitreal Injection of Bevacizumab
Mozayan, A., & Farah, S. (2013) · Ophthalmic Surgery, Lasers and Imaging Retina · doi:10.3928/23258160-20121221-08 · Cited by 22 · cited 2×
“Time to resolution 2–12 weeks [11, 15, 17, 18, 20, 24] Extremely variable”
BackgroundZou, P., Povoski, S. P., Hall, N. C., Carlton, M. M., Hinkle, G. H., Xu, R. X., Mojzisik, C. M., Johnson, M., Knopp, M. V., Martin, E. W., et al. (2010) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-8-65 · Cited by 20
Successful Management of Choroidal Metastasis With Intravitreal Ranibizumab Injections
Detorakis, Ε. T., Agorogiannis, G. I., Drakonaki, E. E., Tsilimbaris, M. K., & Pallikaris, I. G. (2012) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/15428877-20120517-03 · Cited by 20 · cited 1×
“Hindawi Publishing Corporation Mediators of Inflammation Volume 2013, Article ID 943409, 6 pages http://dx.doi.org/10.1155/2013/943409”
BackgroundInfluential
Research works printed but not linked: 5
- 2012, Ophthalmic Surgery Lasers Imaging, 43, e47
- 10.3928/15428877-20110603-04 · DOI · Paper page
- 2013, Ophthalmology, 120, 1100.5
- 1997, Journal of Interferon and Cytokine Research, 17, S15
- 1987, Laboratory Investigation, 56, 583
Cited by
Aptamers as targeted therapeutics: current potential and challenges
Zhou, J., & Rossi, J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.199 · Cited by 2,221
Pharmacokinetic aspects of retinal drug delivery
del Amo, E. M., Rimpelä, A.-K., Heikkinen, E., Kari, O. K., Ramsay, E., Lajunen, T., Schmitt, M., Pelkonen, L., Bhattacharya, M., Richardson, D., et al. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.12.001 · Cited by 693
Wang, X., Fan, W., Li, N., Ma, Y., Yao, M., Wang, G., He, S., Li, W., Tan, J., Lu, Q., et al. (2023) · Genome Biology · doi:10.1186/s13059-023-02931-y · Cited by 288
“Repeated intraocular injections may lead to various adverse effects [7].”
BackgroundOcclusive Retinal Vasculitis Following Intravitreal Brolucizumab
Witkin, A. J., Hahn, P., Murray, T. G., Arevalo, J. F., Blinder, K. J., Choudhry, N., Emerson, G. G., Goldberg, R. A., Kim, S. J., Pearlman, J., et al. (2020) · Journal of VitreoRetinal Diseases · doi:10.1177/2474126420930863 · Cited by 183
“(%) White Black 24 (96) 1 (4) Location, No.”
BackgroundInfluentialErratum: Aptamers as targeted therapeutics: current potential and challenges
Zhou, J., & Rossi, J. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.86 · Cited by 163
Metadata
- Authors
- Agrawal, S., Joshi, M., & Christoforidis, J. B.
- Affiliations
- Banner - University Medical Center Tucson (US)
- Corresponding author
- Christoforidis, John B.
- Venue
- Mediators of Inflammation
- Publisher
- Wiley
- Published
- 2013
- Volume
- 2013
- Pages
- 1-6
- ISSN
- 0962-9351 (ISSN-L)
- 1466-1861
- PMC
- PMC3836427
- OpenAlex
- W2022562553
- Cited by
- 83
- References
- 55
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 11 · 2023: 5 · 2022: 6 · 2021: 9 · 2020: 8 · 2019: 7 · 2018: 5 · 2017: 5 · 2016: 7 · 2015: 8 · 2014: 2
- FWCI
- 0.99
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Mediators of Inflammation (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- vitreous inflammation, sterile endophthalmitis, anti-VEGF therapy, intravitreal injection, bevacizumab, ranibizumab, pegaptanib, aflibercept, vascular endothelial growth factor, eye safety, pathogenesis
- MeSH terms
- Bevacizumab, Ranibizumab, Humans, Infant, Newborn, Inflammation, Endophthalmitis, Recombinant Fusion Proteins, Retinal Diseases, Risk, Vitreous Body, Angiogenesis Inhibitors, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor A, Aptamers, Nucleotide, Intravitreal Injections, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.